Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study

Massimo Gentile, Giovanna Cutrona, Laura Mosca, Serena Matis, Sonia Fabris, Marta Lionetti, Fiorella Ilariucci, Simona Zupo, Caterina Musolino, Luciano Levato, Stefano Molica, Francesco Di Raimondo, Iolanda Vincelli, Nicola Di Rienzo, Emanuela Anna Pesce, Francesco Angrilli, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort of patients. Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score. To date, 468 Binet A patients were classified as low- (0 positive marker), intermediate- (1 positive marker), or high-risk (2 or 3 positive markers) using the progression risk score. The 3-year PFS probability was 91.7%, 82.9%, and 57.4% for low-, intermediate-, and high-risk (P

Original languageEnglish
Pages (from-to)743-750
Number of pages8
JournalAmerican Journal of Hematology
Volume89
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Disease-Free Survival
Biomarkers
Transcriptome
Multicenter Studies
Observational Studies

ASJC Scopus subject areas

  • Hematology

Cite this

Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients : Results of the multicenter O-CLL1-GISL study. / Gentile, Massimo; Cutrona, Giovanna; Mosca, Laura; Matis, Serena; Fabris, Sonia; Lionetti, Marta; Ilariucci, Fiorella; Zupo, Simona; Musolino, Caterina; Levato, Luciano; Molica, Stefano; Di Raimondo, Francesco; Vincelli, Iolanda; Di Rienzo, Nicola; Pesce, Emanuela Anna; Angrilli, Francesco; Federico, Massimo; Neri, Antonino; Ferrarini, Manlio; Morabito, Fortunato.

In: American Journal of Hematology, Vol. 89, No. 7, 2014, p. 743-750.

Research output: Contribution to journalArticle

Gentile, Massimo ; Cutrona, Giovanna ; Mosca, Laura ; Matis, Serena ; Fabris, Sonia ; Lionetti, Marta ; Ilariucci, Fiorella ; Zupo, Simona ; Musolino, Caterina ; Levato, Luciano ; Molica, Stefano ; Di Raimondo, Francesco ; Vincelli, Iolanda ; Di Rienzo, Nicola ; Pesce, Emanuela Anna ; Angrilli, Francesco ; Federico, Massimo ; Neri, Antonino ; Ferrarini, Manlio ; Morabito, Fortunato. / Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients : Results of the multicenter O-CLL1-GISL study. In: American Journal of Hematology. 2014 ; Vol. 89, No. 7. pp. 743-750.
@article{dc5c94a85c9745488a117970e1b20efb,
title = "Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study",
abstract = "A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort of patients. Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score. To date, 468 Binet A patients were classified as low- (0 positive marker), intermediate- (1 positive marker), or high-risk (2 or 3 positive markers) using the progression risk score. The 3-year PFS probability was 91.7{\%}, 82.9{\%}, and 57.4{\%} for low-, intermediate-, and high-risk (P",
author = "Massimo Gentile and Giovanna Cutrona and Laura Mosca and Serena Matis and Sonia Fabris and Marta Lionetti and Fiorella Ilariucci and Simona Zupo and Caterina Musolino and Luciano Levato and Stefano Molica and {Di Raimondo}, Francesco and Iolanda Vincelli and {Di Rienzo}, Nicola and Pesce, {Emanuela Anna} and Francesco Angrilli and Massimo Federico and Antonino Neri and Manlio Ferrarini and Fortunato Morabito",
year = "2014",
doi = "10.1002/ajh.23729",
language = "English",
volume = "89",
pages = "743--750",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients

T2 - Results of the multicenter O-CLL1-GISL study

AU - Gentile, Massimo

AU - Cutrona, Giovanna

AU - Mosca, Laura

AU - Matis, Serena

AU - Fabris, Sonia

AU - Lionetti, Marta

AU - Ilariucci, Fiorella

AU - Zupo, Simona

AU - Musolino, Caterina

AU - Levato, Luciano

AU - Molica, Stefano

AU - Di Raimondo, Francesco

AU - Vincelli, Iolanda

AU - Di Rienzo, Nicola

AU - Pesce, Emanuela Anna

AU - Angrilli, Francesco

AU - Federico, Massimo

AU - Neri, Antonino

AU - Ferrarini, Manlio

AU - Morabito, Fortunato

PY - 2014

Y1 - 2014

N2 - A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort of patients. Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score. To date, 468 Binet A patients were classified as low- (0 positive marker), intermediate- (1 positive marker), or high-risk (2 or 3 positive markers) using the progression risk score. The 3-year PFS probability was 91.7%, 82.9%, and 57.4% for low-, intermediate-, and high-risk (P

AB - A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort of patients. Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score. To date, 468 Binet A patients were classified as low- (0 positive marker), intermediate- (1 positive marker), or high-risk (2 or 3 positive markers) using the progression risk score. The 3-year PFS probability was 91.7%, 82.9%, and 57.4% for low-, intermediate-, and high-risk (P

UR - http://www.scopus.com/inward/record.url?scp=84902791001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902791001&partnerID=8YFLogxK

U2 - 10.1002/ajh.23729

DO - 10.1002/ajh.23729

M3 - Article

C2 - 24711230

AN - SCOPUS:84902791001

VL - 89

SP - 743

EP - 750

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -